Previous studies have demonstrated that CCR2 high expression in many malignant tumor tissues was positively correlated with disease progression and worse outcomes, including prostate cancer [11, 12], lung cancer [13], liver cancer [14], breast cancer [15], colorectal cancer [16] and pancreatic cancer [17]. The gene discussed is CCR2; the disease is familial pancreatic carcinoma.